

# Original Research Article

## DETECTION OF *Chlamydia trachomatis* IN DONATED BLOOD AT REGIONAL BLOOD TRANSFUSION CENTRE, ELDORET, KENYA

### ABSTRACT

**Aim:** To detect *Chlamydia trachomatis* in donated blood at Regional Blood Transfusion center, Eldoret.

**Methodology:** A random selection blood sample was done for this study. Blood bags were numbered 1-87 and picked amongst unnumbered blood bags by each donor in order of donation. The samples obtained were subjected to centrifugation and serum used in the immunoassay test by using the *Chlamydia trachomatis* IgG/IgM Elisa test kit.

**Result:** This study showed that *C. trachomatis* was present in 8% (7 samples) of the blood samples analyzed and 92% were found to be negative.

**Conclusion:** With 8% of the samples testing positive for *Chlamydia trachomatis* this indicated that some of the blood donated to the Regional Transfusion Center is contaminated.

**Keywords:** *Chlamydia trachomatis*, Blood, Transfusion

### 1. INTRODUCTION

*Chlamydia* is a genus of pathogenic bacteria that are obligate intracellular parasites. Chlamydia infections are the most common bacterial sexually transmitted diseases in humans and are the leading cause of infectious blindness worldwide [1]. *Chlamydia trachomatis*, commonly known as chlamydia, is one of four bacterial species in the genus Chlamydia.

*C. trachomatis* is globally a major cause for sexually transmitted diseases (STDs) including, urogenital and Chlamydia. Chlamydia is one of the most common sexually transmitted infections worldwide affecting about 4.2% of women and 2.7% of men [2]. *C. trachomatis* cause various infections that include trachoma (conjunctivitis which is the most reported reason for blindness globally), pneumonic infections, and genital infections in people of both sexes and conjunctivitis in newborns. It is estimated that there are over 50 million new cases of *C. trachomatis* infection annually [3]. However another study done in 2015 showed that about 61 million new cases occurred globally [4].

*C. trachomatis* causes various contaminations among is donated blood. A study estimated that about 92 million blood donations are collected per year in different parts of the world. In addition, WHO published that 39 countries in the world still do not routinely test for transfusion-transmissible infections (TTIs) including HIV, Hepatitis B, Hepatitis C and syphilis. About 47% donations in low-income countries are screened in laboratories which do not have capacity for *C. trachomatis* contamination [5]. Blood transfusion centers are expected to provide blood that is free of

39 contaminants. However, without this there is likeliness of transmitting fatal agents like *C. trachomatis*  
40 that may result in deadly diseases that may be found in blood [6].

41 Weström [7] asserted that one of the factors that may contribute to unnoticed *C. trachomatis*  
42 contamination of donated blood is that its infections are to a bigger percentage asymptomatic. This  
43 has commonly been reported in both males and females with about 50% males and 75% females of  
44 those affected having no symptoms.

## 45 **2. MATERIALS AND METHODS**

### 46 **2.1. Sample Collection**

47 Blood samples used in the study were collected aseptically using venipuncture techniques by  
48 qualified personnel following the Pendergraph procedure of phlebotomy [8].

49 Use of aseptic techniques were observed to preserve the integrity of the specimen. Blood samples  
50 obtained were labelled with the donors code for *C. trachomatis* test. The sample blood obtained was  
51 subjected to centrifugation to separate the serum from the other blood components. The serum  
52 samples were then refrigerated at 2<sup>o</sup>-8<sup>o</sup>C in RBTC Hematology Laboratory to be used in the  
53 immunoassay test by using the *Chlamydia trachomatis* IgG/IgM Elisa test kit to find out the presence  
54 of *C. trachomatis* in donated blood using the ELISA procedure as shown below.

### 55 **2.2. Sample Processing**

56 10ml of blood sample from each donor was centrifuged at 1600rpm for 15 minutes. This was done  
57 when clotting had occurred and within 1 hour after blood sample was drawn. Serum was then used for  
58 the indirect immunoassay test.

#### 59 **2.2.1. Indirect Immunoassay**

##### 60 **Preparations and Assay Procedure**

61 The washing solution was prepared in advance. This was done by using distilled water to fill 50 ml of  
62 20x washing solution up to 1 liter after which the solution was warmed up to 37°C in the washing  
63 concentrate during storage before diluting. Once diluted, it was stored at 4°C.

##### 64 **The Indirect Immunoassay Procedure**

65 The incubator was set at 37°C and all the reagents brought to room temperature before use  
66 (approximately 1hour), without removing the plate from the bag. The components were then shaken  
67 well.

68 The plate was removed from the package and the numbers of wells to be employed determined that  
69 is: Four wells for the controls; two for the cut off serum and one each for the negative and positive  
70 sera. Wells not required for the test were returned to the pouch and sealed

71

72 For IgG test, 100 µl of serum diluent **2** was added to all wells followed by 5 µl of each sample, 5 µl of  
73 positive control **3G**, 5 µl of cut off control **4G** (in duplicate) and 5 µl of negative control **5G** into the  
74 corresponding wells. The plates were then shaken in a plate shaker for 2 min in order to achieve a  
75 homogenous mixture of the reagents. A sealing sheet was then used to cover the wells and incubated  
76 at 37°C for 45 min.

77

78 For IgM test, 25 µl of VIRCELL IgG sorbent was added to each of the required wells, except for the  
79 wells where controls will be dispensed. 5 µl of sample was added and then 75 µl of the serum diluent  
80 **2** to each well. Control wells were prepared by adding first 100 µl of the serum diluent **2** to each well  
81 and then 5 µl of the positive control **3M**, 5 µl of the cut off control **4M** (in duplicate) and 5 µl of the  
82 negative control **5M** to the corresponding wells. This was followed by plate shaking in a plate shaker

83 for 2 min in order to achieve a homogenous mixture of the reagents. A sealing sheet was then used to  
84 cover the wells and incubated at 37°C for 45 min.

85

86 After incubation, the seal was removed, liquid aspirated from all wells and washed five times with 0.3  
87 ml of washing solution **9** per well and any remaining liquid was drained off. 100 µl of IgG conjugate  
88 solution **6G** or IgM conjugate solution **6M** was immediately added into each well and a sealing sheet  
89 used to cover followed by incubation at 37°C for 30 minutes.

90

91 After 30mins the seal was removed, liquid aspirated from all wells and washed five times with 0.3 ml  
92 of washing solution **9** per well. Any remaining liquid was drained off and 100 µl of substrate solution **7**  
93 immediately added into each well followed by incubation at room temperature for 20 minutes  
94 protected from light. After incubation 50 µl of stopping solution **8** was immediately added into all wells  
95 and finally readings were carried out within 1 hour of stopping.

96

### 97 **3. RESULTS**

#### 98 **To detect *Chlamydia trachomatis* in donated blood using IgG/IgM Elisa kit**


99 Samples with indexes below 9 were considered as not having IgG or IgM specific antibodies against  
100 *C. trachomatis* while samples with indexes above 11 will be considered as having IgG or IgM specific  
101 antibodies against *C. trachomatis*. Therefore this study showed that *C. trachomatis* in blood donors'  
102 samples at RBTC was found to be present in 8% (7 samples) of the blood samples analyzed at RBTC  
103 and 92% were found to be negative. (Table 1).

104 **Table 1: Antibodies Present in donor samples indicating *Chlamydia trachomatis* infection**

Antibodies against <i>C. trachomatis</i>			
Week	Donor No.	IgM Antibodies	IgG Antibodies
1	1-25	-	-
2	32	-	+
	37	-	+
	41	+	+
	48	+	-
3	53	+	-
	59	-	+
4	86	-	+

105 - =Absence of antibodies, + = Presence of antibodies

106 **Figure 1: Proportion of donors' samples with *Chlamydia trachomatis* at RBTC**



107

108

109 **Associations Between *C. trachomatis* and Selected Variables**

110 A *chi-square* test was performed to determine the dependency between *C. trachomatis* and selected  
 111 variables. With the significance level at 0.05 the statistics revealed that having irregular sexual  
 112 partners dependency with occurrence of *C. trachomatis*  $X^2 (1) = 4.667$ ,  $p=0.031$  but not significant.  
 113 (Table 2)

114

115 **Table 2: *Chi-square* tests**

Characteristics		<i>C. trachomatis</i> status		Chi Square tests		
		Positive N=7 Out of 87 samples	Pearson Chi-Square	Valid cases	Asymp. Sig. (2-sided)	
<b>Age groups</b>	Below 30 years	4	0.236	87	0.627	
	30 years and above	3				
<b>Gender</b>	Male	2	0.706	87	0.401	
	Female	5				
<b>Marital status</b>	Single	4	0.173	87	0.677	
	Non-singles	3				
<b>Education level</b>	Primary and below	1	0.401	87	0.527	
	Secondary and above	6				
<b>Employment status</b>	Unemployed	4	1.055	87	0.304	
	Self-employed and/ Employed	3				
<b>Irregular sexual partners</b>	No	3	4.667	87	<b>0.031*</b>	
	Yes	4				

116 **Note:** Non-singles include married, divorced, separated or widowed

117 \* Significant at  $p<0.05$ .

118 **4. DISCUSSION**

119 The presence of *C. trachomatis* in blood samples was determined based upon the reaction of  
 120 antibodies in the donor sample tested with the antigen adsorbed on the polystyrene surface. Unbound

121 immunoglobulins were washed off, this was then followed by an enzyme anti-human globulin binding  
122 the antigen-antibody complex in a second step. After a new washing step, bound conjugate was  
123 developed with the aid of a substrate solution (TMB) to render a blue colored soluble product which  
124 turned into yellow after adding the acid stopping solution [9]. IgG/IgM antibody detection are markers  
125 for a Chlamydia-positive immune response, either for current, chronic or past infections. The assay  
126 used in this study was the COMP (Complexes of Outer Membrane Proteins) of *C. trachomatis*, free  
127 from LPS which is responsible for most cross-reaction with other Chlamydia species.

128 Occurrence of IgM antibodies without IgG being present is an indication of primary infection while  
129 presence of IgG antibodies without IgM antibodies in the blood sample is an indication of re-infection  
130 or presence of previous infections since IgG antibodies persists in the body for a long period of time.  
131 Presence of both IgG and IgM antibodies in the sample shows an ongoing infection.

132 In a study from Makkah Saudi Arabia, 8.7% of the women were positive for IgG antibodies to *C.*  
133 *trachomatis* with antibody indexes of 1.4–2.0 [10]. Low prevalence in Saudi patient population may be  
134 due to the adherence of strict moral principles and code of ethics in Saudi Arabia. In comparison to  
135 these study 71.4% of women were positive for both IgG/IgM antibodies which is much higher.

136 Similarly, it has been shown in the USA and Europe that demographic factors which increase the risk  
137 of chlamydial infection include youth, single marital status and multiple sexual partners [11].  
138 Therefore, a closer attempt should be made to correlate risk factors and disease entity when  
139 screening for *C. trachomatis*.

140 According to a study done by CDC,[12] on the prevalence of *C. trachomatis* among the adults, the  
141 highest rates is between 20 to 24 years old, however the age-specific rates for women was as low as  
142 to 16 to 26 years old. This current study however slightly differs from the statistics by CDC. The age  
143 between 20 to 29 years of age showed the highest prevalence.

144 Multiple partnerships may increase the likelihood of encountering a sexually transmitted pathogen  
145 through the increased probability of choosing a partner with infection, while having new or casual  
146 sexual contacts may be related to increased risk because of a reduced familiarity between partners  
147 [13]. The present study conquers with the later however it is not conclusive as per the statistics on the  
148 *chi square* table.

## 149 **5. CONCLUSION**

150 The findings of this study therefore indicates that some blood donated to the Regional Transfusion  
151 Center was contaminated with *Chlamydia trachomatis* with 8% of the total samples indicating positive  
152 for *C. trachomatis* infection while 92 % were negative. Moreover the age group of between 20 to 29  
153 years old had the greatest percentage of those with *C. trachomatis*. Having multiple irregular number  
154 of sexual partners increases the chances of having *Chlamydia trachomatis* infection. However this is  
155 not conclusive according to the statistics of this study.

## 156 **REFERENCES**

- 157 [1]. Ryan, KJ. & Ray CG. (2004). Sherris Medical Microbiology (4th Ed.). McGraw Hill. pp. 463–70.  
158 [2]. Newman, L., Rowley, J., Vander Hoorn, S., Wijesooriya, N. S., Unemo, M., Low, N, &  
159 Temmerman, M. (2015). Global estimates of the prevalence and incidence of four curable sexually  
160 transmitted infections in 2012 based on systematic review and global reporting. *PloS one*, 10(12),  
161 e0143304.  
162  
163 [3]. Centers for Disease Control and Prevention. (2003). *Sexually Transmitted Disease Treatment*  
164 *Guidelines*. MMWR, Vol. 51, No.RR-6, pp.:1-78.  
165

- 166 [4]. Global Burden of Disease (2015). "Global, regional, and national incidence, prevalence, and years  
167 lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global  
168 Burden of Disease Study 2015". *Lancet*. 388 (10053)
- 169 [5]. World Health Organization. (2008). Prevalence and incidence of selected sexually transmitted  
170 infections; *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *syphilis* and *Trichomonas vaginalis*
- 171 [6]. Mudasaar, M., (2008) Transfusion-transmitted diseases Fellow, Department of Internal Medicine,  
172 Division of Geriatrics, Duke University Health System: 10.1046/j.1537-2995.2000.40030335.  
173
- 174 [7]. Weström, L. A. R. S., Joesoef, R., Reynolds, G. L. A. D. Y. S., Hagdu, A., & Thompson, S. E.  
175 (1999). Pelvic inflammatory disease and fertility. *Sexually transmitted diseases*, 19(4), 185-192.
- 176 [8]. Pendergraph, G. E., & Pendergraph, C. B. (1998). *Handbook of phlebotomy and patient service*  
177 *techniques*. Lippincott Williams & Wilkins.
- 178 [9]. Bas, S., Muzzin, P., Ninet, B., Bornand, J. E., Scieux, C., & Vischer, T. L. (2001). Chlamydial  
179 serology: comparative diagnostic value of immunoblotting, microimmunofluorescence test, and  
180 immunoassays using different recombinant proteins as antigens. *Journal of clinical microbiology*,  
181 39(4), 1368-1377.
- 182 [10]. Ghazi, HO., Daghestani, MH., Mohamed, MF. Seropositivity of *chlamydia trachomatis* among  
183 Saudi pregnant women in Makkah, *J Family Community Med* 2006; 13 (2):61–4.
- 184
- 185 [11]. Pramanik -Mania, J., Kerkar, S., Sonawane, S., Mehta, P., & Salvi, V. (2012). Current Chlamydia  
186 trachomatis infection, a major cause of infertility. *Journal of reproduction & infertility*, 13(4), 204.  
187
- 188 [12]. Centers for Disease Control and Prevention (2005). Atlanta, GA: US Department of Health and  
189 Human Services
- 190 [13]. Vranic, S. M. (2012). Chlamydia trachomatis Infections of the Adults. In *Sexually Transmitted*  
191 *Infections*. InTech.